摘要
随着恶性肿瘤对人类健康的危害性逐年增加,研发新颖抗肿瘤药物迫在眉睫。微生物来源的埃博霉素类药物具有微管稳定作用,其选择性高、活性强、毒性较低,有望取代紫杉醇成为新一代抗肿瘤药物,具有巨大的市场前景。鉴于政治、科技、经济、文化环境的不同,其市场情况及研发动态也出现一定变化。本文对当前这类药物国内外生产情况、研发动态及市场前景进行分析,并提供建议,预期能为企业生产经营方向的选择、医院临床用药等起到导向作用。
Due to the hazards of malignant tumor on human health are increasing year by year, the research and development of new antitumor drugs was needed imminently. Epothilones drugs from Microorganisms had a role in microtubule stability, which had strong activity, high selectivity, low toxicity. Epothilones was expected to replace the paclitaxel to be a new generation of antitumor drugs, which had great market prospect. As the differences in the economy, politic, technology and culture, their markets and development had certainly changed. The production situation at home and abroad, research ＆ development（R＆D） and market dynamics of the current this kind drug were analyzed, At the same time, a number of recommendations was given, it was expected that there will be some guide for the relevant enterprises and government departments to formulate business strategies and clinical application medicine.
出处
《中国处方药》
2012年第5期26-37,共12页
Journal of China Prescription Drug
